Published in J Infect Dis on December 01, 1999
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med (2002) 3.26
Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol (2004) 2.41
Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol (2004) 2.20
Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by Neisseria meningitidis serogroup C. J Clin Microbiol (2001) 2.12
Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis (2002) 1.92
Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis (2003) 1.81
Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev (2010) 1.70
The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun (2005) 1.68
Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines (2009) 1.54
Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev (2006) 1.53
Multiple-locus variable-number tandem repeat analysis of Neisseria meningitidis yields groupings similar to those obtained by multilocus sequence typing. J Clin Microbiol (2006) 1.48
Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol (2000) 1.48
Meningococcal disease: changes in epidemiology and prevention. Clin Epidemiol (2012) 1.48
Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol (2005) 1.47
Sequence diversity of Neisseria meningitidis 16S rRNA genes and use of 16S rRNA gene sequencing as a molecular subtyping tool. J Clin Microbiol (2002) 1.45
The changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccin Immunother (2012) 1.45
A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis (2008) 1.44
Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface (2007) 1.37
How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell (2015) 1.34
Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis (2010) 1.31
Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol (2007) 1.30
Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun (2002) 1.29
Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009. Emerg Infect Dis (2012) 1.26
Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun (2010) 1.24
Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol (2012) 1.20
Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan. BMC Infect Dis (2006) 1.19
Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001. Can J Infect Dis (2002) 1.14
Correlating epidemiologic trends with the genotypes causing meningococcal disease, Maryland. Emerg Infect Dis (2004) 1.14
Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol (2006) 1.11
5' exonuclease assay for detection of serogroup Y Neisseria meningitidis. J Clin Microbiol (2002) 1.10
Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine (2009) 1.08
Whole genome sequencing to investigate the emergence of clonal complex 23 Neisseria meningitidis serogroup Y disease in the United States. PLoS One (2012) 1.07
Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. Ann Clin Microbiol Antimicrob (2004) 1.07
Serological specificities of murine hybridoma monoclonal antibodies against Neisseria meningitidis serogroups B, C, Y, and W135 and evaluation of their usefulness as serogrouping reagents by indirect whole-cell enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (2005) 1.05
Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol (2006) 1.04
Identification of Neisseria meningitidis serogroups Y and W135 by siaD nucleotide sequence analysis. J Clin Microbiol (2003) 1.02
Meningococcal glycoconjugate vaccines. Hum Vaccin (2011) 1.01
Pathogenesis, Therapy, and Prevention of Meningococcal Sepsis. Curr Infect Dis Rep (2002) 1.00
Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation. Clin Vaccine Immunol (2007) 0.99
Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins. J Immunol (2011) 0.99
Clinical features and outcome of sporadic serogroup W135 disease Taiwan. BMC Infect Dis (2006) 0.96
Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect Immun (2003) 0.96
Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera. Clin Diagn Lab Immunol (2004) 0.96
Meningococcal disease in South Africa, 1999-2002. Emerg Infect Dis (2007) 0.95
Genetic basis for biosynthesis of the (alpha 1-->4)-linked N-acetyl-D-glucosamine 1-phosphate capsule of Neisseria meningitidis serogroup X. Infect Immun (2003) 0.95
Analysis of pathogen-host cell interactions in purpura fulminans: expression of capsule, type IV pili, and PorA by Neisseria meningitidis in vivo. Infect Immun (2002) 0.95
Integrating host genomics with surveillance for invasive bacterial diseases. Emerg Infect Dis (2008) 0.95
TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A. Vaccine (2007) 0.95
Evaluation of a fluorescence-based PCR method for identification of serogroup a meningococci. J Clin Microbiol (2003) 0.94
Environmental exposures and invasive meningococcal disease: an evaluation of effects on varying time scales. Am J Epidemiol (2009) 0.94
Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups. Eur J Clin Microbiol Infect Dis (2006) 0.94
Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect Immun (2002) 0.93
Vaccines containing de-N-acetyl sialic acid elicit antibodies protective against neisseria meningitidis groups B and C. J Immunol (2009) 0.93
Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection. Can J Infect Dis Med Microbiol (2009) 0.92
The meningococcus tamed? Arch Dis Child (2002) 0.92
Carriage rates and serogroups of Neisseria meningitidis among freshmen in a University dormitory in Korea. Yonsei Med J (2012) 0.91
Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil. Trans R Soc Trop Med Hyg (2007) 0.90
Potential capsule switching from serogroup Y to B: The characterization of three such Neisseria meningitidis isolates causing invasive meningococcal disease in Canada. Can J Infect Dis Med Microbiol (2005) 0.90
DNA Sequence analysis of the PorB protein of nonserotypeable serogroup C ET-15 meningococci suggests a potential mutational hot spot on their serotype antigens. J Clin Microbiol (2004) 0.89
exl, an exchangeable genetic island in Neisseria meningitidis. Infect Immun (2001) 0.89
Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009. Clin Vaccine Immunol (2011) 0.88
Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development. Clin Vaccine Immunol (2014) 0.88
Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience. Adv Prev Med (2011) 0.88
Bacteraemic pneumonia caused by Neisseria meningitidis serogroup Y. Respir Med Case Rep (2011) 0.88
A decade of invasive meningococcal disease surveillance in Poland. PLoS One (2013) 0.87
Estimating costs associated with a community outbreak of meningococcal disease in a colombian Caribbean city. J Health Popul Nutr (2014) 0.87
Meningococcal Meningitis. Med J Armed Forces India (2011) 0.87
Two strikingly different signaling pathways are induced by meningococcal type IV pili on endothelial and epithelial cells. Infect Immun (2011) 0.86
Vaccination policy in Korean armed forces: current status and future challenge. J Korean Med Sci (2015) 0.85
Space-time cluster analysis of invasive meningococcal disease. Emerg Infect Dis (2004) 0.84
A maternal vaccine against group B Streptococcus: past, present, and future. Vaccine (2013) 0.84
Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985-2002. Epidemiol Infect (2006) 0.84
Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide. Immunology (2003) 0.84
Genotypic and phenotypic characterization of carriage and invasive disease isolates of Neisseria meningitidis in Finland. J Clin Microbiol (2011) 0.84
Fatal acute cellulitis due to Neisseria meningitidis. J Clin Microbiol (2003) 0.83
Invasive meningococcal disease in Scotland, 1994 to 1999, with emphasis on group B meningococcal disease. J Clin Microbiol (2002) 0.83
Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002. J Clin Microbiol (2009) 0.83
Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol (2010) 0.83
Epidemiology of infant meningococcal disease in the United States, 2006-2012. Pediatrics (2015) 0.83
Epidemiology of meningococcal disease, New York City, 1989-2000. Emerg Infect Dis (2003) 0.83
Invasive meningococcal disease in children in Jerusalem. Epidemiol Infect (2007) 0.82
Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health (2007) 0.81
Meningitis caused by Neisseria Meningitidis, Hemophilus Influenzae Type B and Streptococcus Pneumoniae during 2005-2012 in Turkey. A multicenter prospective surveillance study. Hum Vaccin Immunother (2014) 0.80
Active immunization in the United States: developments over the past decade. Clin Microbiol Rev (2001) 0.80
A case of meningococcal sepsis and meningitis with complement 7 deficiency in a military trainee. Infect Chemother (2013) 0.79
Clonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688. J Clin Microbiol (2012) 0.79
Vaccination against meningitis B: is it worth it? Drugs Context (2013) 0.78
Incidence and etiological agents of bacterial meningitis among children <5 years of age in two districts of Romania. Eur J Clin Microbiol Infect Dis (2004) 0.78
Isolated septic arthritis: meningococcal infection. J R Soc Med (2003) 0.78
Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response. Infect Immun (2003) 0.78
How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines. J Immunol Res (2015) 0.77
Neurologic aspects of infections in international travelers. Neurologist (2005) 0.77
Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries. PLoS One (2016) 0.77
Regulation of capsule in Neisseria meningitidis. Crit Rev Microbiol (2015) 0.76
Epidemiology of meningococcal disease in Switzerland, 1999-2002. Eur J Clin Microbiol Infect Dis (2004) 0.76
Primary Meningococcal Septic Arthritis of the Knee by Neisseria meningitidis Serotype Y. West Indian Med J (2014) 0.75
Pasteurized milk as a vehicle of infection in an outbreak of listeriosis. N Engl J Med (1985) 11.94
Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis (2001) 11.73
Meningococcal disease. N Engl J Med (2001) 8.50
Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med (2000) 8.05
Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med (2000) 6.58
Serological response to "Rochalimaea henselae" antigen in suspected cat-scratch disease. Lancet (1992) 6.48
A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med (1993) 6.18
Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A (1997) 5.90
Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med (1997) 5.73
Cat scratch disease in Connecticut. Epidemiology, risk factors, and evaluation of a new diagnostic test. N Engl J Med (1993) 5.45
Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA (2001) 4.90
Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa. Lancet (2000) 4.35
The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis (1998) 4.33
Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med (2000) 4.20
Epidemic leptospirosis associated with pulmonary hemorrhage-Nicaragua, 1995. J Infect Dis (1998) 3.97
The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis (1999) 3.92
Legionella pneumonia in the United States: the distribution of serogroups and species causing human illness. J Infect Dis (1984) 3.81
Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA (1999) 3.69
Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA (1995) 3.64
Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ (1992) 3.57
Predicting Mycobacterium avium complex bacteremia in patients infected with human immunodeficiency virus: a prospectively validated model. Clin Infect Dis (1994) 3.30
The molecular epidemiology of cholera in Latin America. J Infect Dis (1993) 3.26
Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis (1998) 3.18
Water-related nosocomial pneumonia caused by Legionella pneumophila serogroups 1 and 10. J Infect Dis (1985) 3.16
Nonmenstrual toxic shock syndrome: a review of 130 cases. Ann Intern Med (1982) 3.12
Use of polymerase chain reaction for detection of toxigenic Vibrio cholerae O1 strains from the Latin American cholera epidemic. J Clin Microbiol (1992) 3.10
Toxic-shock syndrome not associated with menstruation. A review of 54 cases. Lancet (1982) 3.10
Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. JAMA (1991) 3.09
Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med (2000) 3.09
Use of automated sequencing of polymerase chain reaction-generated amplicons to identify three types of cholera toxin subunit B in Vibrio cholerae O1 strains. J Clin Microbiol (1993) 3.01
Reduction in the incidence of human listeriosis in the United States. Effectiveness of prevention efforts? The Listeriosis Study Group. JAMA (1995) 2.97
Long-term outcomes of persons with Lyme disease. JAMA (2000) 2.96
Efficacy of meningococcal vaccine and barriers to vaccination. JAMA (1998) 2.92
Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med (2000) 2.85
Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis (1996) 2.85
Role of foods in sporadic listeriosis. I. Case-control study of dietary risk factors. The Listeria Study Group. JAMA (1992) 2.82
Risk factors for group B streptococcal disease in adults. Ann Intern Med (1995) 2.78
Clinical signs for the recognition of children with moderate or severe anaemia in western Kenya. Bull World Health Organ (1997) 2.73
Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study. Lancet (2000) 2.67
Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis. Proc Natl Acad Sci U S A (2001) 2.66
Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis (2001) 2.65
Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health (2000) 2.57
Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis (1999) 2.57
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet (1992) 2.52
Comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis: experience at an acquired immune deficiency syndrome reference center in Rio de Janeiro, Brazil. Am J Respir Crit Care Med (2000) 2.51
Magnetic separation techniques in diagnostic microbiology. Clin Microbiol Rev (1994) 2.41
Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA (2001) 2.40
Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers. J Infect Dis (1985) 2.39
Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet (1985) 2.39
A new Legionella species, Legionella feeleii species nova, causes Pontiac fever in an automobile plant. Ann Intern Med (1984) 2.35
The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet (1996) 2.35
Candida dubliniensis fungemia: the first four cases in North America. Emerg Infect Dis (2000) 2.34
Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group. Ann Intern Med (1992) 2.33
Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis (1999) 2.32
Reactivity of serum from patients with suspected legionellosis against 29 antigens of legionellaceae and Legionella-like organisms by indirect immunofluorescence assay. J Infect Dis (1983) 2.28
Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA (1994) 2.28
Cat scratch disease in the United States: an analysis of three national databases. Am J Public Health (1993) 2.26
Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil. Projecto Praça Onze Study Group. J Acquir Immune Defic Syndr (2000) 2.19
Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome. Evidence for additional toxins. JAMA (1985) 2.16
Role of foods in sporadic listeriosis. II. Microbiologic and epidemiologic investigation. The Listeria Study Group. JAMA (1992) 2.15
Toxic shock syndrome surveillance in the United States, 1980 to 1981. Ann Intern Med (1982) 2.14
Bacillary angiomatosis and bacillary splenitis in immunocompetent adults. Ann Intern Med (1993) 2.14
Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by Neisseria meningitidis serogroup C. J Clin Microbiol (2001) 2.12
Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression. JAMA (1994) 2.11
Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group. J Clin Microbiol (1996) 2.08
Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA (1988) 2.06
Role of M protein in adherence of group A streptococci. Infect Immun (1991) 2.05
Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis (2000) 2.05
The 1997 AAP guidelines for prevention of early-onset group B streptococcal disease. American Academy of Pediatrics. Pediatrics (1997) 2.04
The accuracy of late antenatal screening cultures in predicting genital group B streptococcal colonization at delivery. Obstet Gynecol (1996) 1.99
The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J (1991) 1.99
Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex. Emerg Infect Dis (2000) 1.97
Pilus- and non-pilus-mediated interactions of Haemophilus influenzae type b with human erythrocytes and human nasopharyngeal mucosa. J Infect Dis (1990) 1.97
Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull World Health Organ (1999) 1.96
Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med (1998) 1.96
Comparison of ribotyping and multilocus enzyme electrophoresis for subtyping of Listeria monocytogenes isolates. J Clin Microbiol (1994) 1.96